LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of CVRx, Inc. ("CVRx†or the "Company†) (NASDAQ: CVRX) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CVRX, INC. (CVRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is the Investigation About? On April 7, 2025, CVRx announced first quarter results, including revenue of only $12. ...

Core Insights - CVRx, Inc. announced the schedule for scientific presentations on Barostim therapy at the Technology and Heart Failure Therapeutics 2026 meeting, highlighting its focus on innovative neuromodulation solutions for cardiovascular diseases [1][6] Group 1: Scientific Presentations - The presentations will include late-breaking clinical data, oral sessions, and posters that cover real-world outcomes, cardiac energetics, hospitalization impact, left ventricular ejection fraction (LVEF) improvements, and changes in advanced hemodynamics [2] - Dr. Dmitry Yaranov will present data from the REBALANCE Registry, which evaluates the safety and benefits of Barostim therapy in a commercial setting, focusing on six-month outcomes from over 400 patients [3] Group 2: Clinical Trials and Studies - CVRx will host a satellite program featuring updates on the REBALANCE Registry, the BREATHE-HF trial, and the BENEFIT-HF trial, with the latter being a landmark randomized study supported by CMS Category B IDE coverage [4] - The BENEFIT-HF trial aims to evaluate the impact of Barostim in a broader heart failure population, with a primary endpoint of all-cause mortality and heart failure decompensation events, and enrollment is expected to begin in the first half of 2026 [4] Group 3: Company Overview - CVRx is a commercial-stage medical device company that has developed Barostim, the first FDA-approved neuromodulation technology for improving heart failure symptoms [6] - Barostim is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery, designed to restore balance to the autonomic nervous system and reduce heart failure symptoms [6]

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether CVRx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 7, 2025, CVRx anno ...

Core Viewpoint - CVRx, Inc. is under investigation for potential violations of federal securities laws, which may impact investors who have suffered losses [1] Company Summary - The Law Offices of Howard G. Smith are representing CVRx investors in exploring claims to recover losses incurred [1]

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of CVRx, Inc. ("CVRx†or the "Company†) (NASDAQ: CVRX) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CVRX, INC. (CVRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is the Investigation About? On April 7, 2025, CVRx announced first quarter results, including revenue of only $12. ...

Financial Performance - The company incurred net losses of $53.3 million and $60.0 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $590.7 million as of December 31, 2025[219]. - The company reported net cash used in operating activities of $40.2 million and $39.1 million for the fiscal years ended December 31, 2025 and 2024, respectively[312]. - The company anticipates that existing cash, cash equivalents, short-term investments, and revenue will be sufficient to meet capital requirements for at least the next two years[312]. - The company may need to seek additional funds in the future, which may not be available on acceptable terms or at all[312]. - The company is restricted from paying dividends or making distributions on its capital stock under its Loan and Security Agreement with Innovatus Life Sciences Fund I, LP[314]. - The company’s operating results may vary significantly annually or quarterly, potentially impacting stock price[316]. - The company has approximately $483.7 million in federal net operating loss (NOL) carryforwards and $9.7 million in state NOL carryforwards as of December 31, 2025[323]. - Federal NOLs began expiring in 2021, while state NOLs began expiring in 2020, which may limit the company's ability to utilize these carryforwards[324]. - The company generated federal and state tax credit carryforwards of approximately $10.3 million and $1.9 million, respectively, with federal credits beginning to expire in 2021 and state credits starting in 2028[323]. Market and Competition - The company relies heavily on Barostim for revenue, which is expected to continue to be the primary source of income, with limited brand recognition and market acceptance[222]. - The company faces intense competition from established medical device companies with greater resources, which could hinder its ability to gain market share for Barostim[230]. - The healthcare industry is experiencing significant cost reform, leading to consolidation that may pressure the company to provide price concessions for its product, Barostim[251]. - Economic conditions, including inflation and potential recession, could adversely affect demand for Barostim and the company's ability to raise capital[275]. - The company estimates the total market opportunity for Barostim based on the number of patients with HFrEF and assumed selling prices, but acknowledges that these estimates may not be accurate[273][274]. Sales and Marketing - The company expects to continue incurring significant sales and marketing, research and development, and regulatory expenses as it grows its U.S. commercial sales force and expands marketing efforts for Barostim[219]. - The company plans to expand its U.S. direct sales and marketing organization to drive future revenue growth, which requires significant investment in hiring and training sales personnel[223]. - The company needs to effectively demonstrate the merits of Barostim to physicians to drive adoption and sales, as physician acceptance is critical for success[224]. - The company anticipates ongoing challenges in recruiting and retaining qualified sales personnel due to high competition in the labor market[233]. Manufacturing and Supply Chain - The company is investing in enhancing manufacturing processes to meet increasing demand for Barostim, which is essential for maintaining sales forecasts[240]. - The company operates solely from its manufacturing facility in Minneapolis, Minnesota, which poses risks of operational disruption due to potential disasters or vandalism[244]. - Manufacturing output must increase to meet expected customer demand; challenges include manufacturing yields, quality control, and component supply[253]. - The company is dependent on third-party manufacturers and suppliers, which exposes it to risks related to supply shortages and performance degradation[235]. - The company relies on third-party suppliers for components, and any issues with these suppliers could affect production and profitability[243]. Regulatory and Compliance - The company must navigate complex regulatory approval processes in various jurisdictions, which can vary significantly and may delay product commercialization[263]. - The company is subject to extensive governmental regulation, which could increase costs and delay the introduction of new products[338]. - Compliance with the EU Medical Device Regulation (MDR) is required, with final approval for Barostim's compliance issued on April 9, 2025[335]. - The company must continue to submit updates for any substantial changes to the design or quality system to meet MDR requirements[335]. - The company is subject to extensive post-market regulations by the FDA and foreign authorities, and any non-compliance could result in recalls, fines, or other penalties[345]. - The company must report adverse medical events to the FDA and European regulators, and failure to do so could lead to significant sanctions and harm its reputation[350]. Risks and Challenges - The company faces risks from international operations, including compliance with trade regulations and potential penalties for non-compliance[247]. - The company is subject to product liability claims, which could adversely affect its financial results and reputation[264]. - Cybersecurity threats are increasing, and any significant disruption to the company's information technology systems could negatively impact operations and financial results[271]. - The company may experience operational disruptions due to pandemics or outbreaks of infectious diseases, impacting sales and production[282][285]. - The development and use of AI technologies present risks that could affect operations and patient care, as well as expose the company to legal and regulatory challenges[287]. - The company may face significant costs and distractions from potential intellectual property litigation, which could hinder commercialization efforts[288][289]. - The company may face challenges in protecting its intellectual property rights globally, which could adversely affect its competitive position[304]. - The company may be subject to claims regarding the wrongful use or disclosure of trade secrets, which could result in costly litigation and distract management[306]. Strategic Initiatives - The company may pursue strategic collaborations or acquisitions to enhance its product offerings, but there are risks associated with the success and integration of these efforts[276][278]. - Changes in executive leadership can disrupt operations and affect relationships with customers and suppliers, impacting financial performance[266]. - The company has opted to delay implementing new accounting standards, which may result in financial statements that are not directly comparable to those of other public companies[367]. Investor Relations - The company does not currently intend to pay dividends on its common stock, meaning returns for investors will depend on stock price appreciation[376]. - As of December 31, 2025, executive officers, directors, and significant stockholders owned approximately 37% of the outstanding voting stock, allowing them to exert significant control over shareholder matters[371]. - The company's stock price is expected to fluctuate significantly, influenced by various factors, including market volatility and potential litigation risks[363].

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices by CVRx, Inc. and its officers, following disappointing financial results and significant stock price declines [1]. Financial Performance - On April 7, 2025, CVRx reported weaker than expected preliminary first quarter results, leading to a stock price drop of $5.34 per share, or 46.3%, closing at $6.20 on April 8, 2025 [1]. - On May 8, 2025, CVRx announced weak first quarter results and reduced its full year revenue guidance, resulting in a further stock price decline of $3.01 per share, or 38.7%, closing at $4.77 on May 9, 2025 [1]. Management Commentary - CVRx's CEO indicated that many new sales representatives are still in early development stages, which contributed to the disappointing performance [1]. - The CEO also mentioned that recent changes in the salesforce were more significant than initially anticipated, with 25% of current territory managers hired between December and March [1]. Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [1].

Financial Data and Key Metrics Changes - Fourth quarter revenue was $16 million, representing a growth of 4% year-over-year, while full year revenue reached $56.7 million, reflecting a 10% increase [3][17] - Gross profit for the fourth quarter was $13.8 million, an increase of 8%, with gross margin rising to 86% from 83% a year ago [19] - Net loss for the fourth quarter was $11.9 million, or $0.46 per share, compared to a net loss of $10.7 million, or $0.43 per share in the same quarter of the previous year [22] Business Line Data and Key Metrics Changes - Revenue generated in the U.S. was $14.9 million, an increase of 4%, with revenue units totaling 478, up from 460 in the prior year [17] - Revenue in Europe was $1.1 million, a 10% increase, with total revenue units rising to 49 from 41 [18] Market Data and Key Metrics Changes - The addressable market for Barostim therapy is estimated at $10.5 billion, with only less than 1% penetration [6] - The ongoing BENEFIT-HF trial could potentially triple the addressable market to approximately $30 billion if successful [13] Company Strategy and Development Direction - The company focused on three strategic priorities: building a world-class sales organization, driving deep adoption in targeted centers, and reducing barriers to adoption [7] - The transition to Category I CPT codes is expected to improve patient access and reimbursement predictability, which is a significant milestone for the company [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sales team's ability to execute the program-focused selling approach as they gain experience [8] - The initiation of the BENEFIT-HF trial is seen as a significant development that will enhance visibility and credibility in the heart failure community [25] Other Important Information - The company amended its debt facility to extend the maturity date to 2031 and provide access to additional capital [15][23] - The company expects total revenue for 2026 to be between $63 million and $67 million, with a gross margin between 84% and 86% [23] Q&A Session Summary Question: Can you talk about the initial sites for the BENEFIT-HF trial? - The trial will involve about 150 centers in the U.S. and some in Germany, with a mix of existing and new commercial sites [28] Question: How should we expect the growth of active accounts to trend through 2026? - The company expects to add around 3 active territories on a quarterly basis, leading to high single-digit account additions on a net basis each quarter in 2026 [31] Question: Do you see any scenario where the trial can be a tailwind for the core business? - Management believes there will be a goodwill effect and credibility boost from the trial, positively impacting the core business [35] Question: Can you share any anecdotal examples of how the Category I code has helped lower barriers to treatment? - Early signs show that payers who previously rejected prior authorizations are beginning to approve them, indicating positive progress [38] Question: What gives you confidence in the revenue guidance for 2026? - The company has seen sequential growth from Q1 to Q4 in 2025 and expects to return to growth after a seasonal dip from Q4 to Q1 [41] Question: Can you discuss the path to profitability? - The company has sufficient cash reserves and access to additional capital, with a focus on generating leverage through sales productivity [75]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $16 million, representing a 4% increase year-over-year, while full year revenue reached $56.7 million, reflecting a 10% growth [3][17] - Gross profit for the fourth quarter was $13.8 million, an increase of 8%, with gross margin rising to 86% from 83% a year ago [19] - Net loss for the fourth quarter was $11.9 million, or $0.46 per share, compared to a net loss of $10.7 million, or $0.43 per share in the prior year [22] Business Line Data and Key Metrics Changes - Revenue generated in the U.S. was $14.9 million, a 4% increase, with revenue units totaling 478, up from 460 in the prior year [17] - Revenue in Europe was $1.1 million, a 10% increase, with total revenue units rising to 49 from 41 [18] Market Data and Key Metrics Changes - The addressable market for Barostim therapy is estimated at $10.5 billion, with only less than 1% penetration [6] - The potential market could triple to approximately $30 billion if the BENEFIT-HF trial is successful, expanding the addressable patient population from 339,000 to over 980,000 [13] Company Strategy and Development Direction - The company focused on three strategic priorities: building a world-class sales organization, driving deep adoption in targeted centers, and reducing barriers to adoption [7] - The transition to Category I CPT codes is expected to improve patient access and reimbursement predictability, effective January 1, 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sales team's ability to execute the program-focused selling approach as they gain experience [8] - The initiation of the BENEFIT-HF trial is seen as a significant development that will enhance visibility and credibility in the heart failure community [25] Other Important Information - The company amended its debt facility to extend the maturity date to 2031 and provide access to additional capital [15][23] - The company expects total revenue for 2026 to be between $63 million and $67 million, with a gross margin between 84% and 86% [23][24] Q&A Session Summary Question: Can you talk about the initial sites for the BENEFIT-HF trial? - The trial will involve about 150 centers in the U.S. and some in Germany, with a mix of existing and new commercial sites [28] Question: How should we expect the growth of active accounts to trend through 2026? - The company expects to add around three active territories quarterly, leading to high single-digit account additions on a net basis each quarter in 2026 [31] Question: Do you see any scenario where the trial can be a tailwind for the core business? - Management believes there will be a goodwill effect and credibility boost from the trial, positively impacting the core business [35] Question: Can you share any anecdotal examples of how the Category I code has helped lower barriers to treatment? - Early signs show that payers who previously rejected prior authorizations are beginning to approve them, indicating positive progress [38] Question: What gives you confidence in the revenue guidance for 2026? - The company has seen sequential growth from Q1 to Q4 in 2025 and expects to return to growth after a seasonal dip from Q4 to Q1 [41] Question: How do you expect to manage the business to profitability over the medium term? - The company has sufficient cash reserves and plans to generate leverage by increasing sales productivity while managing expenses [75]